Teva CEO Outlines Biopharma Strategy and $700M Cost-Saving Plan
Teva Pharmaceutical Industries is accelerating its transition from a generics-focused company to one centered on biopharmaceuticals, with innovative sales now reaching about $1 billion per quarter. CEO Richard Francis emphasized the 'Pivot to Growth' strategy, which includes stabilizing the generics business and advancing R&D while maintaining disciplined capital allocation. The company aims for a 30% operating margin by 2027 through cost-efficiency measures expected to save $700 million after investment. Teva's gross margin has improved from 48% at the start of Francis' tenure to around 55%, driven largely by higher-margin innovative products. Teva plans regular product launches supported by growth brands and a robust pipeline, including biosimilars and candidates like duvakitug and ecopipam. The CEO noted that while operating margin is expected to rise beyond 2027, the company will balance this with continued investment in its R&D portfolio.
Tickers: $TEVA
Topics: Biopharmaceuticals Cost Savings Generics Pipeline Growth